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SUMMARY
Psoriasis is thought to be a T cell-mediated skin disease and the cutaneous lymphocyte antigen (CLA) is
an important skin homing epitope for T cells. We have studied the relationship between disease severity
(PASI) and phenotypic analysis of T cells in the blood of 36 patients with psoriasis focusing on the
expression of CLA, VLA-4 and CD25 on CD41 and CD81 T cells. The patients had a higher frequency
of circulating CLA1 CD81 cells than healthy controls. Furthermore, a much stronger correlation was
observed between PASI and the frequency of CLA1 CD81 than CLA1 CD41 T cells. The frequency of
CLA1D81 T cells correlated more strongly with redness, thickness and scaling of the skin lesions than
the total affected body surface area. In contrast to CLA the T cell expression of VLA-4 did not
demonstrate any such correlation. Finally, the expression of the activation marker CD25 on CD81 T
cells showed a strong correlation with disease severity in patients with moderate to severe psoriasis
(PASI . 10) but such correlation was not observed for CD41 T cells. These findings support the notion
that circulating CLA1 CD81 T cells may play an important role in the pathogenesis of psoriasis.
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INTRODUCTION
Psoriasis is a common chronic skin disease in which T cells are
thought to play a key pathogenic role [1–3]. Cutaneous
lymphocyte antigen (CLA) is a carbohydrate epitope that interacts
with E-selectin [4] and is a product of fucosyl transferase VII
dependent post-translational modification of the P-selectin
glycoprotein ligand 1 (PSGL-1) [5,6]. In humans CLA is normally
detected on less than 20% of peripheral blood T cells [7–9]. CLA
positive cells are found in healthy skin [7] and most of skin-
infiltrating T cells express this epitope [10] while T cells
infiltrating other tissues are predominantly CLA negative [11].
It has therefore been postulated that CLA controls the influx of
memory T cells to cutaneous sites [10,11]. Accordingly, it has
been reported that T cells in psoriatic lesions express CLA,
whereas T cells infiltrating arthritic joints did not [12]. This
suggests that CLA may play a pathogenic role in psoriasis. It has
recently been reported that injection of superantigen activated
human T cells can induce psoriatic lesions in uninvolved skin
transplanted on to SCID mice [13,14]. CLA expression has also
been reported in this model [15]. Increased expression of the
tissue non-specific adhesion molecule very late antigen VLA-4
has also been observed in psoriasis [16,17].
It has been reported that patients with active psoriasis have
increased frequency of T cells expressing the alpha chain of the
IL-2 receptor (CD25), a marker of activated T cells [18,19] and
the level of serum CD25 has shown a moderate correlation with
disease severity in psoriasis [20]. Other activation markers and
immunological mediators in serum that have shown correlation
with PASI in psoriasis include E-selectin [21–23], TNF-alpha [24]
and neopterin [25].
It has been suggested that CD81 T cells may play an important
pathogenic role in psoriasis [13]. In this study we demonstrate that
the frequency of CLA1 CD81 T cells in the peripheral blood of
psoriatic patients correlates strongly with disease severity as
measured by the PASI score, and that this also applies for CD251
CD81 T cells and disease severity in patients with moderate to
severe psoriasis (PASI . 10).
MATERIALS AND METHODS
Study population
Thirty-six patients with chronic plaque psoriasis were evaluated
by the same physician for the Psoriatic Area and Severity Index
(PASI) and the individual components of this score were also
recorded separately. None of these patients had guttate type
lesions at the time of the study. In the PASI scoring system [26],
the area of psoriatic involvement of the head (H), trunk (T), upper
limbs (U) and lower limbs (L) is given a numerical value from 0 to
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6, and in each area erythema (E), infiltration (I) and desquamation
(D) are assessed on a scale of 0–4. The PASI is calculated from
the following formula: PASI  0·1(EH 1 IH 1 DH)AH 1 0·3(E-
T 1 IT 1 DT)AT 1 0·2(EU 1 IU 1 DU)AU 1 0·4(EL 1 IL*-
DL)AL. The total affected body surface area (TBS) was also
calculated. The patients had not been on any treatment for at least
1 month prior to their recruitment to the study and none had any
evidence of psoriatic arthritis. Blood samples were obtained but
clinical assessment was done without knowledge of the results of
the T cell analysis. Thirteen individuals with no history of
psoriasis were included in the study as healthy controls. The study
was approved by the Ethics Committee of the Landspı´tali
University Hospital in Reykjavı´k, Iceland.
Isolation of peripheral mononuclear blood cells
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized blood by density gradient. The cells were washed
twice and resuspended in RPMI 1640 (gibco BRL, Life
Technologies, Paisley, UK) supplemented with 2 mm glutamin
(gibco), 100 U/ml penicillin/100 mg streptomycin (gibco) with
10% human AB serum (The Blood Bank, Landspı´tali University
Hospital, Reykjavı´k, Iceland).
Antibodies
Monoclonal antibodies (MoAbs) to the following surface antigens
conjugated with fluorescein isothyocyanate (FITC) or phycoery-
thrin (PE) were used: anti-CD25-PE, anti-CD4-FITC, anti-CD4-
PE, anti-CD8-FITC, anti-CD8-PE anti-CD49d/VLA-4a -PE (Bec-
ton Dickinson, Oxford, UK) and anti-CLA-(HECA-452)-FITC
(Pharmingen, Oxford, UK). FITC and PE-conjugated mouse IgG1
were used as isotype controls.
Double immunofluorescence staining and flow cytometry analysis
The PMBC (1  105) were double-stained with the FITC- and
PE-conjugated monoclonal antibodies for 30 min on ice and
washed twice in phosphate buffer saline (PBS) before fixation in
0·5% formalin. Stained cells were analysed by flow cytometry
using a FACScan (Becton Dickinson). The data were analysed by
Cell Quest softwaree (Becton Dickinson).
Statistical analysis
Statistical significance was determined by Student’s t-test or
Mann–Whitney rank sum test. When equal variance was not
observed correlations were determined by the Spearman’s rank
order correlation (r) using the SigmaStat 2·01 (Jandel Scientific,
Erkrath, Germany). P-values below 0·05 were considered
significant.
RESULTS
Frequency of CLA1 CD81 T-cells correlated strongly with PASI
There was no overall difference in the frequencies of CD41 and
CD81 T cells in the peripheral blood of the psoriatic patients and
the healthy controls. However, the patients had a significantly
higher frequency of CLA1 CD81 T cells compared to the healthy
controls (P  0·029), while the frequency of CLA1 CD41 T cells
was similar (Fig. 1). Furthermore, the PASI score correlated with
the frequency of T cells expressing CLA (r  459, P  0·005)
(Table 1, Fig. 2a) and this was due mainly to a strong correlation
between PASI and CLA1 CD81 T cells (r  0·635, P , 0·001).
This applied equally when the frequency of CLA1 T cells was
expressed as a percentage of the total T cells or a percentage of
CD81 T cells (data not shown). As shown in Table 1 all the
individual components that the PASI score is based upon showed
a correlation with the frequency of CLA1 CD81 T cells.
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Fig. 1. The frequency of CLA1 CD41 (a) and CLA1 CD81 (b) T cells in
the blood of healthy controls and psoriatic patients. The frequencies are
expressed as a percentage of the total T cells. Each box plot represents the
mean/median and the 25th and 75th percentiles. The error bars represent
the lowest and the highest values that are not outliers (outside the 5th/95th
percentiles.
Table 1. Spearman’s correlation between T cell subsets in the blood and the total and individuals component of the PASI score and total affected body
surface area (TBS)
T cell subsets
Total PASI TBS Redness Thickness Scaling
r P r P r P r P r P
Total CLA1 T cells 0·459 0·005 0·400 0·016 0·412 0·014 0·457 0·006 0·479 0·004
CLA1 CD41 0·402 0·015 0·382 0·022 0·330 0·053 0·402 0·017 0·408 0·015
CLA1 CD81 0·635 , 0·001 0·471 0·004 0·614 , 0·001 0·607 , 0·001 0·716 , 0·001
Total VLA-41 T cells 0·438 0·143 0·462 0·123 0·291 0·369 0·046 0·881 0·105 0·734
VLA-41 CD41 0·448 0·136 0·483 0·105 0·309 0·339 0·056 0·860 0·073 0·818
VLA-41 CD81 0·123 0·683 0·308 0·317 0·387 0·221 0·369 0·245 0·382 0·233
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However, it should be noted that this correlation was not as
striking for the total affected body surface area as for the other
components of the PASI score that reflect disease activity, namely
the redness, thickness and scaling (Table 1). Again, these
associations were much stronger for the CD81 T cells. In
contrast, no significant correlation was observed between any of
the disease severity parameters and the adhesion molecule VLA-4,
neither for CD41 nor CD81 T cells (Table 1).
The frequency of CD251 CD81 T-cells correlated with PASI in
patients with moderate to severe psoriasis.
The T cells activation marker CD25 was also evaluated separately
for the CD41 and CD81 T cell populations but there was no
overall difference in the frequency of these subpopulations
between the patients and the healthy controls (data not shown).
Furthermore, the frequencies of the CD251 subpopulations did
not show a significant correlation with the PASI score when all
the patients were analysed (data not shown). However, when those
patients who had a relatively severe psoriasis (PASI . 10) were
analysed separately, the frequency of circulating CD251 CD81 T
cells correlated strongly (P  0·007) with PASI, while such
correlation was not observed for CD251 CD41 T cells
(P  0·178) (Fig. 3).
DISCUSSION
In this study we demonstrate for the first time a strong correlation
between the extent and severity of psoriasis (PASI) and the
frequency of circulating CD81 T cells expressing the skin homing
epitope CLA. Furthermore, in patients with severe disease, the
frequency of circulating CD251 CD81 T cells correlated with the
PASI score while this did not apply to CD251 CD41 T cells. In
contrast, the expression of the tissue non-specific adhesion
molecule VLA-4 did not correlate with PASI. Increased frequency
of CLA1 T cells in peripheral blood of psoriatic patients has been
reported before [27], but in another study such an increase for
CD41 or CD81 T cells was not detected [28]. However, that study
involved only 10 patients and the findings were not analysed in
relation to disease severity nor treatment. We have found that
treatment can have a marked influence on CLA expression
(manuscript in preparation).
CD81 T-cells have been implicated in the pathogenesis of
psoriasis because of the strong association with the HLA class I
antigen Cw6 [29,30]. Furthermore, it has recently been suggested
that CD81 positive NK T cells may play an important role in the
generation of psoriatic lesions [31,32]. Our findings are consistent
with this possibility, although we have not analysed the CLA1
CD81 T cells for NK markers. Thus, although CD41 T-cells may
be necessary for initiating psoriatic skin lesions [13], CD81 T-
cells could play an important role in relation to the disease activity
in terms of redness, thickness and scaling of the skin lesions [33].
It should be noted in this context that the frequency of the CLA1
CD81 T cells showed a stronger correlation with these parameters
of disease activity than with the size of the area of affected skin
(Table 1). Thus, interactions of relatively few CD41 T cells with
antigen-presenting cells could create the microenvironment
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Fig. 2. Correlation between disease severity and the expression of CLA1 T cells; (a) PASI versus total CLA1 T cells, (b) PASI versus
CLA1 CD41 T cells and (c) PASI versus CLA1 CD81 T cells. The frequencies are expressed as a percentage of the total T cells.
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required for recruiting CD81 T cells to psoriatic lesions. This
might explain why psoriasis can worsen dramatically in HIV
infected individuals with relatively few circulating CD41 T cells
[34].
The frequency of CLA1 CD81 T cells in the blood seems to
reflect very closely the extent and severity of skin lesions in
psoriatic patients and we are not aware of any laboratory
parameter that is superior in this respect. It remains to be
determined whether changes in the numbers of circulating CLA1
CD81 T cells is a useful parameter for monitoring therapeutic
trials for patients with psoriasis. Although the observed correla-
tion could be an epiphenomenon, it is possible that the activity and
severity of psoriasis is dependent upon constant recruitment to the
skin of CD81 T cells from the blood. This is also supported by the
correlation observed between the PASI score and the frequency of
CD251 CD81 T cells in the blood of patients with moderate to
severe disease. Our findings clearly call for a simultaneous
comparison of CLA1 T cells in the blood and psoriatic lesions.
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Fig. 3. Correlations between disease severity and the expression of CD251
CD41 (filled circels) and CD251 CD81 (open circles) T cells in patients
with moderate to severe psoriasis (PASI . 10). The frequencies are
expressed as a percentage of the total T cells.
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